Moreover, a study concluded that the CX3CL1-CX3CR1 system in patients with active RA might be sensitive to anti-tumor necrosis factor-alpha therapy and confirmed that CX3CL1 plays a critical role in the pathogenesis of RA, which may validate better therapeutic effects of Infliximab on C-type patients characterized by CD8+T cells compared to other types (57). The gene discussed is CX3CR1; the disease is rheumatoid arthritis.